News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Trastuzumab deruxtecan in HER2-positive advanced Breast Cancer
Sep 19, 2024, 12:03

Trastuzumab deruxtecan in HER2-positive advanced Breast Cancer

Dana-Farber’s Breast Oncology Center shared on X:

“Hot off the Press!

Trastuzumab deruxtecan in HER2-positive advanced Breast Cancer with or without Brain Metastases practice changing results from a phase 3b/4 trial.”

Breast Cancer

Source: Dana-Farber’s Breast Oncology Center/X

brain metastasis Breast Cancer breast oncology cancer Dana-Farber’s Breast Oncology Center OncoDaily Oncology Trastuzumab deruxtecan
Special Coverage
Insight
Sep 26, 2024, 03:48
Winette Van Der Graaf: How can RWD and trials support evidence together?
Insight
Sep 26, 2024, 03:43
Stephen Chun: In depth special episode on HN005 and LU005 at ASTRO24
Opinion
Sep 26, 2024, 03:39
Honored to have Dr. Filipa Lynce sharing her insights - The IBC Network Foundation
Insight
Sep 26, 2024, 03:28
Estela Rodriguez: University of Miami MDMPH mentee Kyle Edwards presenting AACR Disparities
Blog
Sep 26, 2024, 03:08
Shahrin Ahmed: Five gynaecological cancer symptoms
Blog
Sep 26, 2024, 03:03
Sabina Signoretti on Sarcomatoid RCC at KCRS24 - KidneyCAN
Blog
Sep 26, 2024, 03:00
Julie McCrossin: A session ESTRO meets ASIA - "What is the best immobilisation device?"
Blog
Sep 26, 2024, 02:57
Sabita Jiwnani: Multinational multidisciplinary tumour board for Esophageal Cancer at ISDE2024
Blog
Sep 26, 2024, 02:53
Palliative Care part 2 with Dr. Abrahm is now released - Two Onc Docs
Blog
Sep 25, 2024, 19:39
Christy Brown: Matt Brown has accepted a role with Medtronic Cardiac and Vascular
Blog
Sep 25, 2024, 19:33
Lucjan Wyrwicz: I had privilege to take part in PhD thesis presentation of Cieszymierz Gawiński
Insight
Sep 25, 2024, 18:29
Tanja Obradovic: Ligufalimab plus ivonescimab combined with chemo in the first-line CRC patients